Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Anakinra (compound)


DrugBank
Identification
Name: Anakinra
Name (isomeric): DB00026
Drug Type: biotech
Description: A synthetic form of native human IL-1Ra that has an additional methionine residue at its amino terminus.
Synonyms:
IL-1ra; IL1 inhibitor; IL-1RN; Interleukin-1 receptor antagonist protein precursor; IRAP; ICIL-1RA
Brand: Kineret (Amgen Inc)
Category: Immunomodulatory Agents, Antirheumatic Agents
CAS number: 143090-92-0
Pharmacology
Indication: For the treatment of adult rheumatoid arthritis.
Pharmacology:
Used to treat rheumatoid arthritis, Anakinra blocks the biologic activity of IL-1 by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. IL-1 production is induced in response to inflammatory stimuli and mediates various physiologic responses including infl...
show more »
Mechanism of Action: Anakinra binds competitively to the Interleukin-1 type I receptor (IL-1RI), thereby inhibiting the action of elevated levels IL-1 which normally can lead to cartilage degradation and bone resorption.
Absorption: Anakinra had an absolute bioavailability of 95% for healthy adults (n = 11) after a 70 mg subcutaneous bolus injection.
Biotransformation: renal
Half Life: 4-6 hrs
Affected organisms: Humans and other mammals
Interactions
Drug interaction:
TrastuzumabTrastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
ThalidomideThalidomide may increase the adverse effects of Anakinra. Increased risk of serious infection. Concomitant therapy should be avoided.

Targets